# A Comparison of Figure-of-8-Suture vs Manual Compression for Venous Access Closure after Cardiac Procedures: An Updated Meta-Analysis.

Mark Terence Mujer<sup>1</sup>, Abdullah Al-abcha<sup>1</sup>, Jairus Flores<sup>2</sup>, Yehia Saleh<sup>1</sup>, and Peter Robinson<sup>3</sup>

<sup>1</sup>Michigan State University <sup>2</sup>University of the Philippines Manila College of Medicine <sup>3</sup>Pat and Jim Calhoun Cardiology Center

May 18, 2020

# Abstract

Background Manual compression (MC) is the current standard to achieve post-procedural hemostasis in patients who need venous vascular access closure after cardiovascular procedures. Figure-of-8 (F8) suture for venous access closure has been reported to be a safe and efficacious alternative to MC. Methods A systematic search was done using PubMed, Google Scholar, EMBASE, SCOPUS and ClinicalTrials.gov without language restriction up until April 15, 2020 for studies comparing F8 suture vs MC. Risk ratio (RR) and mean difference (MD) with 95% confidence interval (CI) were calculated using a random effects model. Results Time to achieve hemostasis was significantly reduced in the F8 arm [MD -21.04 mins (95% CI: -35.66 to -6.42; p=.005)]. Access site bleeding was significantly lower in the F8 group [RR 0.35 (95% CI: 0.18 to 0.66; p=0.001)] along with a lower incidence of hematoma formation [RR 0.42 (95% CI 0.26 to 0.67; p=0.0003)]. There was no significant difference in rates of fistula or pseudoaneurysm formation between the two groups. Overall access site complications were lower in the F8 arm [RR 0.38 (95% CI: 0.26 to 0.55; p<0.00001)] and the effect was more pronounced for sheaths [?]10 Fr [RR 0.33 (95% CI: 0.18 to 0.60; p=0.0003)]. There was lower post-procedural protamine use in the F8 group [RR 0.07 (95% CI:0.01 to 0.36; p=0.001)]. Conclusion For large-bore venous access closure, the F8 suture results in a shortened time to achieve hemostasis along with a lower overall risk of access site complications and post-procedural protamine use.

**Title:** A Comparison of Figure-of-8-Suture vs Manual Compression for Venous Access Closure after Cardiac Procedures: An Updated Meta-Analysis.

Authors: Mark Terence Mujer MD<sup>1</sup> Abdullah Al-Abcha MD<sup>1</sup>, Jairus Flores MD<sup>2</sup>

, Yehia Saleh MD <sup>1</sup>, Peter Robinson MD<sup>3</sup>

# Affiliations:

<sup>1</sup> Department of Medicine, Michigan State University, East Lansing, MI, USA.<sup>2</sup> University of the Philippines College of Medicine, Manila, Philippines.

<sup>3</sup> Pat and Jim Calhoun Cardiology Center, University of Connecticut, Farmington, CT, USA.

# **Corresponding Author:**

Mark Terence Mujer, MD

Department of Medicine

Michigan State University, 788 Service Road

Room B301, East Lansing, MI 48824, USA

Email address: Mujermar@msu.edu

Phone number: (517)-580-2080

Fax: (517)-432-2759

ORCID ID: 0000-0001-8148-0883

Key Words: Figure of Eight Suture, Manual Compression, Venous Closure.

# **Contributorship Statement:**

MM, AA and YS conceptualized the work, gathered and interpreted the data, and drafted the initial manuscript. JF created the tables and figures. PR performed a critical revision of the manuscript.

MM and PR finalized submitted material.

Funding: No funding was received for this manuscript.

Competing Interests: All authors declare that there is no conflict of interest.

Acknowledgement: None.

A Comparison of Figure-of-8-Suture vs Manual Compression for Venous Access Closure after Cardiac Procedures: An Updated Meta-Analysis.

ABSTRACT

#### Background

Manual compression (MC) is the current standard to achieve post-procedural hemostasis in patients who need venous vascular access closure after cardiovascular procedures. Figure-of-8 (F8) suture for venous access closure has been reported to be a safe and efficacious alternative to MC.

#### Methods

A systematic search was done using PubMed, Google Scholar, EMBASE, SCOPUS and ClinicalTrials.gov without language restriction up until April 15, 2020 for studies comparing

F8 suture vs MC. Risk ratio (RR) and mean difference (MD) with 95% confidence interval (CI) were calculated using a random effects model.

#### Results

Time to achieve hemostasis was significantly reduced in the F8 arm [MD -21.04 mins (95% CI: -35.66 to -6.42; p=.005)]. Access site bleeding was significantly lower in the F8 group [RR 0.35 (95% CI: 0.18 to 0.66; p=0.001)] along with a lower incidence of hematoma formation [RR 0.42 (95% CI 0.26 to 0.67; p=0.0003)]. There was no significant difference in rates of fistula or pseudoaneurysm formation between the two groups. Overall access site complications were lower in the F8 arm [RR 0.38 (95% CI: 0.26 to 0.55; p<0.00001)] and the effect was more pronounced for sheaths [?]10 Fr [RR 0.33 (95% CI: 0.18 to 0.60; p=0.0003)]. There was lower post-procedural protamine use in the F8 group [RR 0.07 (95% CI:0.01 to 0.36; p=0.001)].

#### Conclusion

For large-bore venous access closure, the F8 suture results in a shortened time to achieve hemostasis along with a lower overall risk of access site complications and post-procedural protamine use.

#### Introduction

In patients undergoing cardiac procedures, the use of large sheath sizes for venous vascular access is not uncommon. Manual compression is the current standard to achieve post-procedural hemostasis. Although some studies have previously reported favorable outcomes in utilizing arterial vascular closure devices for venous access closure, data on venous vascular closure devices are limited.

Figure-of-8 (F8) suture is an alternative approach for large-bore venous access closure. Prior studies have evaluated the safety and efficacy of the F8 suture technique through venography or vascular ultrasound. (1-3) The first reported use of the F8 suture was done by Bagai and Zhao who used the technique to achieve adult femoral venous access hemostasis and reported success in large caliber sheaths (8 to 21 Fr). As a result, F8 has been used in achieving venous hemostasis with sheaths as large as 24 Fr. (1)

In the F8 suture, a large curved needle with a 0-silk suture is passed through the subcutaneous tissue around 5-10 mm under the access sheath with care taken not to insert the needle deep enough as to ligate the femoral vein or artery. A significant amount of subcutaneous tissue is included to contribute to compression and hemostasis. The needle is then brought cranially to the sheath insertion point and is inserted again in the same initial direction through the subcutaneous tissue, hence a figure of eight stitch is performed [Figure 1]. After the sheaths are removed, the suture is tightened and knotted. The site is observed for a few minutes without utilization of manual compression. A sterile gauze is placed followed by monitoring for any signs of bleeding. Sutures are typically removed the following morning. (4-6)

Our study sought to determine the efficacy, impact and safety of F8 suture in comparison to manual compression for large-bore venous access closure. Nine studies composed of seven observational and two randomized controlled trials (RCTs) have been included in this updated meta-analysis.

#### Methods2.1 Search Strategy

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines was used in this meta-analysis. A systematic search was done using PubMed, Google Scholar, EMBASE, SCOPUS and ClinicalTrials.gov without language restriction up until April 15, 2020 by two authors (MM and AA). Studies comparing figure-of-8 suture vs manual compression were compared. The search included the following keywords: manual compression, manual pressure, figure of eight, figure of 8, fellow's stitch, z-stitch, venous closure, vascular closure.

#### 2.2 Study Selection

The following criteria were used for study selection: [1] The study was performed on adults [?] 18 years of age. [2] The study compared figure-of-eight suture vs manual compression. [3] The study reported atleast one clinical outcome.

# 2.3 Data Extraction

Disagreements between the two authors (MM and AA) were resolved through internal discussion. The following details were collected from each study: Author, design, study population, male sex, age, mean CHA2DS2VASc score, laboratory parameters such as pre-procedural international normalized ratio (INR) and post-procedural activated clotting time (ACT), type of procedure, location of access sites, number of access sites and procedural success rate.

#### 2.4 Clinical Outcomes

The study collected and evaluated the following clinical outcomes: [1] time to hemostasis [2] access site complications [3] fistula formation [4] pseudoaneurysm formation [5] access site bleeding [6] access site hematoma [7] post-procedural protamine use.

#### 2.5 Statistical Analysis

Review Manager (RevMan), version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) was used for statistical analysis. The DerSimonian-Laird random-effects model was used to estimate the risk ratios (RR)

and mean difference (MD) with the corresponding 95% confidence interval (CI). Two-sided p values <0.05 were considered statistically significant. Higgins and Thompson I<sup>2</sup> statistic was used to assess heterogeneity.

#### **Results3.1 Search Results**

A PRISMA flow chart has been included [Figure 2]. A total of 121 citations were identified after an intensive search process, 23 articles were assessed for eligibility and 14 were excluded after screening. Nine studies were found to be eligible based on the inclusion criteria.(4-12)

# 3.2 Study Characteristics

In this meta-analysis, 9 eligible studies were included, composed of 7 observational and 2 RCTs with a total of 2,338 patients. The majority of the study population were males. 1,175 (50.26%) of patients received the F8 suture of which mean  $\pm$  SD age ranged from  $55 \pm 12.4$  to  $63 \pm 11$  years and baseline INR  $\pm$  SD ranged from  $1.4 \pm 0.5$  to 2.6 + 0.6. The majority of the procedures done were AF catheter ablation. Access sites reported were the left and right femoral veins. The success rate of the F8 suture ranged from 91.7% to 100% in the included studies

# [Table 1].

# **3.3 Outcomes**

 ${\bf 3.3.1}$  Time to Hemostasis

Time to achieve hemostasis was significantly reduced in the F8 arm [MD -21.04 mins (95% CI: -35.66 to -6.42; p=.005)] [Figure 3.1].

3.3.2 Overall Access Site Complications

Overall access site complications were lower in the F8 arm [RR 0.38 (95% CI:0.26 to 0.55; p<0.00001)] [Figure 3.2].

3.3.3 Access Site Complications for Sheaths [?] 10 Fr

Access site complications for sheaths [?]10 Fr were lower in the F8 arm [RR 0.33 (95% CI: 0.18 to 0.60; p=0.0003)] [Figure 3.3].

# 3.3.4 Fistula Formation

There was no significant difference in the rate of fistula formation [RR 0.67 (95% CI: 0.18 to 2.41; p=0.54)] between the two groups [Figure 3.4].

# 3.3.5 Pseudoaneurysm Formation

There was no significant difference in the occurrence of pseudoaneurysm [RR 0.47 (95% CI 0.16 to 1.42; p=0.18)] [Figure 3.5].

# 3.3.6 Access site Hematoma

Access site hematoma formation was lower in the F8 arm [RR 0.42 (95% CI: 0.26 to 0.67; p=0.0003)] [Figure 3.6].

# **3.3.7** Access Site Bleeding

Access site bleeding was significantly lower in the F8 group [RR 0.35 (95% CI: 0.18 to 0.66; p=0.001)] [Figure 3.7].

# 3.3.8 Post-Procedural Protamine Use

Use of protamine after the procedure was significantly lower in the F8 arm [RR 0.07 (95% CI:0.01 to 0.36; p=0.001)] [Figure 3.8].

Test of heterogeneity was low for rates of fistula, hematoma and pseudoaneurysm formation, and access site complications. Test of heterogeneity was moderate for access site bleeding and was high for time to achieve hemostasis and post-procedural protamine use.

#### Discussion

The main findings of our study are the following: [1] Time to achieve hemostasis was significantly shorter in the F8 group. [2] There is no difference between F8 and MC in pseudoaneurysm or fistula formation. [3] Access site hematoma and access site bleeding were lower in the F8 group . [4] Overall access site complications were lower in the F8 group with a more pronounced effect seen in sheaths [?] 10 Fr. [5] Post-procedural protamine use was higher in the manual compression group.

Vascular access site complications are known to occur in cardiac procedures and are associated with increased morbidity and prolonged hospital stay. (13, 14) The use of large venous sheaths, periprocedural anticoagulation and multiple sites of puncture contribute to these complications. A demographic shift towards elderly patients receiving cardiac procedures can contribute to an increase in complication rates. Techniques to achieve effective hemostatic control are thus of paramount importance to prevent these complications. Manual compression is the current standard for venous access closure and has been demonstrated to be effective in achieving post-procedural hemostasis; however, its use is associated with patient discomfort, need for additional staff and a longer patient stay in the procedural lab. (15) A period of absolute bed rest with limited limb movement is required to achieve hemostasis through MC. Various techniques such as pressure dressing and closure devices have been utilized for venous vascular hemostasis and have been reported to be efficacious. These techniques are associated with increased cost, risk of device failure and reported complications such as infections and thromboembolism.(16-22)

The F8 suture has been branded as the "Fellow's Stitch" due to its simple technique compared to other suture delivery systems. (2) F8 can be performed in a very short duration (30-60s), and its failure has been attributed to inadequate knot tie or suture break. (4, 6) Our study demonstrated on average a 21 minute reduction in the time needed to achieve satisfactory hemostasis when utilizing the F8 suture compared to traditional MC. Pracon et al., using doppler-duplex assessment of the groins, reported a slightly compressed mean vein diameter with the F8 stitch in place. This gives insight to the stitch's mechanism of action of utilizing the subcutaneous tissue pad to exert pressure on the puncture site. The pressure exerted by the compression is sufficient for hemostasis but maintains the vein's lumen dimensions. Venous thrombosis is a possible concern with a compressed vein diameter. Cilingiroglu et al demonstrated vasoconstriction at the sheath entry point through venography after F8 closure but vascular ultrasound following suture removal demonstrated resolution of the vasoconstriction along with femoral vein compressibility and the absence of thrombus. (1) Our study sought to determine and compare thromboembolic rates. Five of eight studies included thromboembolism as an outcome but no thromboembolic complications were observed aside from 2 events in the Issa 2015 MC arm, both of which were transient ischemic attacks. (4-6)

The use of F8 resulted in a 62% reduction in overall access site complications. The size of the sheaths used in the included studies varied widely, with reported sizes of up to 22 Fr, demonstrating safety and efficacy across a wide range of large venous sheath sizes. The reduction in access site complications may be explained by a shorter time to hemostasis in comparison to the MC group.

Although there were differences in procedural protocols in the included studies, we found a lower need for post-procedural protamine use in the F8 arm. This can lead to lower rates of thromboembolic complications and prevention of other commonly-reported side effects of protamine use such as anaphylaxis, hypotension and bradycardia. (23) Additional cost for suture material are lower in comparison to the amount saved from the use of protamine sulfate (\$1.53 vs \$7.60) (8)

Aside from outcomes reported in this study, Payne et al reported a reduced time to extubation and a reduced recovery time in the electrophysiology lab in their study with the use of F8 suture in comparison to MC. A subgroup analysis done in the study conducted by Jensen et al. showed a significantly higher rate of vascular complications in the manual compression arm (9.4% vs 0%; p = 0.045) in patients with obesity

(body mass index [?]30 kg/m<sup>2</sup>), a factor which should be considered in the decision to use MC. Of note, most of the studies included patients who underwent ablation for atrial fibrillation. The efficacy and safety of the F8 suture may possibly be greater in patients undergoing procedures which do not require continued anticoagulation.

# 5. Study Limitations

The following limitations should be considered in the interpretation of the results of this meta-analysis. Most of the studies included were observational. Some included studies were nonrandomized and retrospective in nature which may potentially have selection bias. A wide variety of venous sheaths sizes were used in the different studies. Although some studies reported utilizing sheaths < 8 Fr, procedural review showed that they were closed concomitantly with a bigger sheath size utilizing a single F8 suture. 4 studies did not monitor or report post-procedural thromboembolic complications. Included studies had variations in ablation protocols, protamine administration and timing of sheath removal. Publication bias is an inherent characteristic of any meta-analysis.

# 6. Conclusion

F8 is a safe and efficacious alternative to MC in large-bore venous access closure and its use results in a shortened time to hemostasis with a lower overall risk of access site complications and post-procedural protamine use. Further RCTs are needed to confirm these results.

#### TABLES AND FIGURES

 Table 1 Study Characteristics

BudyPerformFeatureFeaturePerformP														
descriptionobservationalfill <th< th=""><th>Study</th><th>Design</th><th></th><th></th><th>FoE ± SD</th><th></th><th>CHADSVAS C</th><th>Sizes Reporte</th><th>INR</th><th>Procedural ACT (seconds)</th><th>Procedures Performed</th><th>Site</th><th>Sites Reporte</th><th>Success Rate of FoE</th></th<>	Study	Design			FoE ± SD		CHADSVAS C	Sizes Reporte	INR	Procedural ACT (seconds)	Procedures Performed	Site	Sites Reporte	Success Rate of FoE
· observational         · observat	Issa 2015		376	123		(48.8	3.0 ± 1.7			326±57.0		4	Left Femoral	98.4%
2017         observational         Image: Ima	Aytemir 2016		200	100		52 (52%)	NR	15 Fr	NR	NR		1	femoral	100%
Process 2018     Restrogenetic field     Start		Retrospective observational	284	179		(68.7	1.9 ± 1.3	8.5 Fr		315 ± 58		3	Left Femoral	100%
Controled trial       Fill	Akkaya 2017		407	ency Ablation (RF) group N=92 Cryoballoo n Ablation(C	(58/63) CB 61	55 (59.7 8%) CB 48	2 (2/2) CB	9.5 Fr 11 Fr CB	1.40 (1.32/ 1.47) CB 1.35 (1.27/	319 (307/330) CB	AF Cryoballoon-based		and Left Femoral Vein CB Right Femoral	100%
Numer 2019         Restrospective observational         104         62.5 ft 0.73         12.6 8.5 ft 0.72         3.07.4         3.07.2 st 20.53         attait forliation         Fermioral Vein         Fermioral vein           Payne 2018         Restrospective observational         104         62.5         62.5.8         14.5         276.58 ± 35.21         Catheter ablation         4         Rept and total fermioral         100%           Kumar 2019         Randomized restricted final         70         35         62.5         21         11 11 ft         NR         290 ± 73         Croballoon-based Arbitrace         3.0 ± 1.0         Rept and Left and         100%	Pracon 2018		90	60		30%	NR	13–14) Range	NR	NR	Appendage Occlusion Mitral Valve Commissurotomy ASD closure Pulmonary Valve Implantation Pulmonary Balloon	NR		91.7%
biservaisonal         Image: Non-Signal (72.5)         Image: Non-Signal	Okada 2018		517	270	63±11		NR			325±34		3	Femoral	100%
controlled trial 9.5 (60%) 11 Fr AF ablation Left	Payne 2018		104	62		(72.5	NR	8 Fr		276.58 ± 35.21		4	Left Femoral	100%
	Kumar 2019		70	35			NR		NR	290 ± 73		3.0 ± 1.0	Left	100%

												Vein	
Jensen 2020	Prospective observational	290	158	66.4 ± 13.2	106 (67.1	NR	14.8 ± 2.8 Fr	NR	NR	Pulmonary Vein Isolation	NR	Femoral Vein	98.7%
					%)					Atrial Flutter Ablation			
										Ablation of SVT			
										VT Ablation			
										Left Atrial Appendage Closure			
										Patent Foramen Ovale Closure			
										Electrophyisological Study			

# Figure 1 Figure of Eight Suture





Figure 2 Prisma Flow Chart



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit <u>www.prisma-statement.org</u>.

Figure 3.1 Overall time to achieve hemostasis

	Fig	ure of	8	Manual	compres	sion		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
lssa 2015	6.8	5.7	123	50.7	12.2	253	25.0%	-43.90 [-45.71, -42.09]	2015	•
Lakshmanadoss 2017	15.4	4.7	179	15.7	4.2	105	25.1%	-0.30 [-1.36, 0.76]	2017	· •
Pracon 2018	0.3	0.1	60	12.25	1.46	30	25.1%	-11.95 [-12.47, -11.43]	2018	•
Payne 2018	7.92	5.69	62	36.09	10.37	42	24.8%	-28.17 [-31.61, -24.73]	2018	• •
Total (95% CI)			424			430	100.0%	-21.04 [-35.66, -6.42]		•
Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z				19, df = 3	8 (P < 0.0	0001);	<sup>2</sup> = 100%	5		-100 -50 0 50 10 Favors figure of 8 Favors manual compression

Figure 3.2 Overall access site complications

	Figure	of 8	Manual compr	ession		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Issa 2015	12	123	31	253	21.5%	0.80 [0.42, 1.50]	2015	
Aytemir 2016	1	100	4	100	2.7%	0.25 [0.03, 2.20]	2016	
Lakshmanadoss 2017	7	179	11	105	12.6%	0.37 [0.15, 0.93]	2017	
Akkaya 2017	4	188	22	219	10.2%	0.21 [0.07, 0.60]	2017	
Okada 2018	13	270	50	247	23.5%	0.24 [0.13, 0.43]	2018	
Pracon 2018	8	60	11	30	15.6%	0.36 [0.16, 0.81]	2018	
Payne 2018	2	62	2	42	3.5%	0.68 [0.10, 4.62]	2018	
Kumar 2019	1	35	1	35	1.8%	1.00 [0.07, 15.36]	2019	
Jensen 2020	4	158	9	132	8.7%	0.37 [0.12, 1.18]	2020	
Total (95% CI)		1175		1163	100.0%	0.38 [0.26, 0.55]		◆
Total events	52		141					
Heterogeneity: Tau <sup>2</sup> = 0	0.06; Chi <sup>2</sup>	= 10.0	1, $df = 8 (P = 0$	.26); I <sup>2</sup> =	20%			0.01 0.1 1 10 100
Test for overall effect: Z	= 5.13 (	P < 0.0	0001)					Favors figure of 8 Favors manual compression

Figure 3.3 Access site complications for sheaths [?] 10 Fr

	Figure	of 8	Manual Compre	ession		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl	
Akkaya 2017	1	96	7	94	8.4%	0.14 [0.02, 1.12]		
Aytemir 2016	1	100	4	100	7.7%	0.25 [0.03, 2.20]	· · · · · · · · · · · · · · · · · · ·	
Jensen 2020	4	158	9	132	27.1%	0.37 [0.12, 1.18]		
Pracon 2018	8	60	11	30	56.8%	0.36 [0.16, 0.81]		
Total (95% CI)		414		356	100.0%	0.33 [0.18, 0.60]	◆	
Total events	14		31					
Heterogeneity: Tau <sup>2</sup> :	= 0.00; Ch	<sup>2</sup> = 0.86	6, df = 3 (P = 0.84	); $ ^2 = 0\%$			tar di da	
Test for overall effect	: Z = 3.63	(P = 0.0	003)				0.01 0.1 1 10 Favors figure of 8 Favors manual	

Figure 3.4 Fistula formation

	Figure	of 8	Manual compr	ession		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	ar M-H, Random, 95% CI
lssa 2015	0	123	0	253		Not estimable	2015	5
Aytemir 2016	0	100	0	100		Not estimable	2016	.6
Lakshmanadoss 2017	2	179	2	105	43.8%	0.59 [0.08, 4.10]	2017	.7
Akkaya 2017	1	188	1	219	21.7%	1.16 [0.07, 18.50]	2017	.7
Payne 2018	1	62	0	42	16.4%	2.05 [0.09, 49.09]	2018	.8
Pracon 2018	0	60	0	30		Not estimable	2018	8
Okada 2018	0	270	0	247		Not estimable	2018	8
Jensen 2020	0	158	2	132	18.1%	0.17 [0.01, 3.45]	2020	20 +
Total (95% CI)		1140		1128	100.0%	0.67 [0.18, 2.41]		
Total events	4		5					
Heterogeneity: Tau <sup>2</sup> = 0	0.00; Chi <sup>2</sup>	= 1.46	df = 3 (P = 0.0)	69); I <sup>2</sup> =	0%			0.01 0.1 1 10 10
Test for overall effect: Z	= 0.62 (	P = 0.5	4)					0.01 0.1 1 10 10 Favors figure of 8 Favors manual compression

Figure 3.5 Pseudoaneurysm formation

	Figure	of 8	Manual compre	ession		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Issa 2015	1	123	3	253	24.1%	0.69 [0.07, 6.52]	2015	
Akkaya 2017	0	188	1	219	12.0%	0.39 [0.02, 9.47]	2017	·
Lakshmanadoss 2017	0	179	2	105	13.3%	0.12 [0.01, 2.43]	2017	• • • • • • • • • • • • • • • • • • • •
Okada 2018	0	270	1	247	12.0%	0.31 [0.01, 7.45]	2018	· · · · · · · · · · · · · · · · · · ·
Payne 2018	1	62	0	42	12.1%	2.05 [0.09, 49.09]	2018	· · · · · · · · · · · · · · · · · · ·
Kumar 2019	1	35	0	35	12.2%	3.00 [0.13, 71.22]	2019	· · · · · · · · · · · · · · · · · · ·
Jensen 2020	0	158	4	132	14.4%	0.09 [0.01, 1.71]	2020	• • • • • • • • • • • • • • • • • • • •
Total (95% CI)		1015		1033	100.0%	0.47 [0.16, 1.42]		
Total events	3		11					
Heterogeneity: Tau <sup>2</sup> = 0	0.00; Chi <sup>2</sup>	= 4.37	df = 6 (P = 0.6)	53); I <sup>2</sup> =	0%			0.01 0.1 1 10 100
Test for overall effect: Z	= 1.34 (	P = 0.1	8)					Favors figure of 8 Favors manual compression

Figure 3.6 Access site hematoma

	Figure	of 8	Manual comp	ression		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M–H, Random, 95% CI
lssa 2015	6	123	16	253	27.0%	0.77 [0.31, 1.92]	2015	
Aytemir 2016	0	100	4	100	2.7%	0.11 [0.01, 2.04]	2016	· · · · · · · · · · · · · · · · · · ·
Akkaya 2017	3	188	18	219	15.5%	0.19 [0.06, 0.65]	2017	
Lakshmanadoss 2017	7	179	11	105	26.8%	0.37 [0.15, 0.93]	2017	
Pracon 2018	2	60	3	30	7.5%	0.33 [0.06, 1.89]	2018	
Okada 2018	2	270	3	247	7.1%	0.61 [0.10, 3.62]	2018	
Payne 2018	1	62	2	42	4.0%	0.34 [0.03, 3.62]	2018	
Kumar 2019	0	35	1	35	2.2%	0.33 [0.01, 7.91]	2019	
Jensen 2020	2	158	3	132	7.2%	0.56 [0.09, 3.28]	2020	
Total (95% CI)		1175		1163	100.0%	0.42 [0.26, 0.67]		◆
Total events	23		61					
Heterogeneity: $Tau^2 = 0$	0.00; Chi <sup>2</sup>	= 4.60	df = 8 (P = 0.	$80); I^2 = 0$	0%			
Test for overall effect: Z	2 = 3.61 (	P = 0.0	003)					0.01 0.1 1 10 100 Favors figure of 8 Favors manual compression

Figure 3.7 Access site bleeding

	Figure	of 8	Manual compr	ession		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
lssa 2015	7	123	40	253	30.3%	0.36 [0.17, 0.78]	2015	
Aytemir 2016	1	100	0	100	3.7%	3.00 [0.12, 72.77]	2016	
Pracon 2018	7	60	10	30	27.4%	0.35 [0.15, 0.83]	2018	
Okada 2018	10	270	46	247	34.5%	0.20 [0.10, 0.39]	2018	
Jensen 2020	2	158	0	132	4.1%	4.18 [0.20, 86.36]	2020	· · · · · · · · · · · · · · · · · · ·
Total (95% CI)		711		762	100.0%	0.35 [0.18, 0.66]		◆
Total events	27		96					-
Heterogeneity: Tau <sup>2</sup> =	= 0.19; Ch	$i^2 = 6.2$	73, df = 4 (P = 6	0.15); I <sup>2</sup> =	= 41%			
Test for overall effect:	Z = 3.26	(P = 0)	.001)					0.01 0.1 1 10 1 Favors figure of 8 Favors manual compression

Figure 3.8 Post-procedural protamine use

	Figure	of 8	Manual compr	ession		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Issa 2015	2	123	192	253	31.4%	0.02 [0.01, 0.08]	←∎
Payne 2018	3	62	42	42	34.9%	0.06 [0.02, 0.16]	
Pracon 2018	4	60	7	30	33.7%	0.29 [0.09, 0.90]	
Total (95% CI)		245		325	100.0%	0.07 [0.01, 0.36]	
Total events	9		241				
Heterogeneity: Tau <sup>2</sup> =	1.68; Cł	$i^2 = 11$	.44, df = 2 (P =	0.003);	$l^2 = 83\%$		0.01 0.1 1 10 10
Test for overall effect:	Z = 3.19	(P = 0	.001)				0.01 0.1 1 10 10 Favors figure of 8 Favors manual compression

#### REFERENCES

1. Cilingiroglu M, Salinger M, Zhao D, Feldman T. Technique of temporary subcutaneous "Figure-of-Eight" sutures to achieve hemostasis after removal of large-caliber femoral venous sheaths. Catheter Cardiovasc Interv. 2011;78(1):155-60.

2. Morgan GJ, Waragai T, Eastaugh L, Chaturvedi RC, Lee KJ, Benson L. The fellows stitch: large caliber venous hemostasis in pediatric practice. Catheter Cardiovasc Interv. 2012;80(1):79-82.

3. Zhou Y, Guo Z, Bai Y, Zhao X, Qin Y, Chen S, et al. Femoral venous hemostasis in children using the technique of "figure-of-eight" sutures. Congenit Heart Dis. 2014;9(2):122-5.

4. Issa ZF, Amr BS. Venous hemostasis postcatheter ablation of atrial fibrillation while under therapeutic levels of oral and intravenous anticoagulation. J Interv Card Electrophysiol. 2015;44(2):97-104.

5. Aytemir K, Canpolat U, Yorgun H, Evranos B, Kaya EB, Sahiner ML, et al. Usefulness of 'figure-ofeight' suture to achieve haemostasis after removal of 15-French calibre femoral venous sheath in patients undergoing cryoablation. Europace. 2016;18(10):1545-50.

6. Pracon R, Bangalore S, Henzel J, Cendrowska-Demkow I, Pregowska-Chwala B, Tarnowska A, et al. A randomized comparison of modified subcutaneous "Z"-stitch versus manual compression to achieve hemostasis after large caliber femoral venous sheath removal. Catheter Cardiovasc Interv. 2018;91(1):105-12.

7. Lakshmanadoss U, Wong WS, Kutinsky I, Khalid MR, Williamson B, Haines DE. Figure-of-eight suture for venous hemostasis in fully anticoagulated patients after atrial fibrillation catheter ablation. Indian Pacing Electrophysiol J. 2017;17(5):134-9.

8. Payne J, Bickel T, Gautam S. Figure-of-eight sutures for hemostasis result in shorter lab recovery time after ablation for atrial fibrillation. Pacing Clin Electrophysiol. 2018.

9. Okada M, Inoue K, Tanaka K, Ninomiya Y, Hirao Y, Oka T, et al. Efficacy and Safety of Figure-of-Eight Suture for Hemostasis After Radiofrequency Catheter Ablation for Atrial Fibrillation. Circ J. 2018;82(4):956-64.

10. Jensen CJ, Schnur M, Lask S, Attanasio P, Gotzmann M, Kara K, et al. Feasibility of the Figureof-8-Suture as Venous Closure in Interventional Electrophysiology: One Strategy for All? Int J Med Sci. 2020;17(7):965-9.

11. Akkaya E, Berkowitsch A, Zaltsberg S, Deubner N, Greiss H, Hain A, et al. Safety and feasibility of percutaneous skin closure using purse-string suture compared with compression bandage after pulmonary vein isolation. J Cardiovasc Electrophysiol. 2017;28(9):1048-57.

12. Kumar V, Wish M, Venkataraman G, Bliden K, Jindal M, Strickberger A. A randomized comparison of manual pressure versus figure-of-eight suture for hemostasis after cryoballoon ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2019;30(12):2806-10.

13. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14(4):528-606.

14. Barbetta I, van den Berg JC. Access and hemostasis: femoral and popliteal approaches and closure devices-why, what, when, and how? Semin Intervent Radiol. 2014;31(4):353-60.

15. Dangas G, Mehran R, Kokolis S, Feldman D, Satler LF, Pichard AD, et al. Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. J Am Coll Cardiol. 2001;38(3):638-41.

16. Geis NA, Pleger ST, Chorianopoulos E, Muller OJ, Katus HA, Bekeredjian R. Feasibility and clinical benefit of a suture-mediated closure device for femoral vein access after percutaneous edge-to-edge mitral valve repair. EuroIntervention. 2015;10(11):1346-53.

17. Mahadevan VS, Jimeno S, Benson LN, McLaughlin PR, Horlick EM. Pre-closure of femoral venous access sites used for large-sized sheath insertion with the Perclose device in adults undergoing cardiac intervention. Heart. 2008;94(5):571-2.

18. Maraj I, Budzikowski AS, Ali W, Mitre CA, Kassotis J. Use of vascular closure device is safe and effective in electrophysiological procedures. J Interv Card Electrophysiol. 2015;43(2):193-5.

19. Shaw JA, Dewire E, Nugent A, Eisenhauer AC. Use of suture-mediated vascular closure devices for the management of femoral vein access after transcatheter procedures. Catheter Cardiovasc Interv. 2004;63(4):439-43.

20. Hamid T, Choudhury TR, Clarke B, Mahadevan VS. Pre-closure of Large-Sized Arterial Access Sites in Adults Undergoing Transcatheter Structural Interventions. Cardiol Ther. 2015;4(1):59-63.

21. Mylonas I, Sakata Y, Salinger M, Sanborn TA, Feldman T. The use of percutaneous suture-mediated closure for the management of 14 French femoral venous access. J Invasive Cardiol. 2006;18(7):299-302.

22. Hermiller JB, Leimbach W, Gammon R, Karas SP, Whitbourn RJ, Wong SC, et al. A prospective, randomized, pivotal trial of a novel extravascular collagen-based closure device compared to manual compression in diagnostic and interventional patients. J Invasive Cardiol. 2015;27(3):129-36.

23. Boer C, Meesters MI, Veerhoek D, Vonk ABA. Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review. Br J Anaesth. 2018;120(5):914-27.